B. Zinman

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
B Zinman, B. Zinman, Bernard Zinman, Bernie Zinman
Publication record
875 papers · 86,883 citations · H-index 131

PAPERS

Baseline Cardiovascular Risk Factor Control in Patients With Type 2 Diabetes and Coronary Disease Versus Stroke: Secondary Analysis of Cardiovascular Outcome Trials
20236 citationsauthor #7
Determinants of sustained stabilization of beta-cell function following short-term insulin therapy in type 2 diabetes
202317 citationsauthor #9
Outcomes in children of women with type 2 diabetes exposed to metformin versus placebo during pregnancy (MiTy Kids): a 24-month follow-up of the MiTy randomised controlled trial.
202337 citationsauthor #5
Generalizability of REDUCE-IT eligibility criteria in a large diabetes cardiovascular outcomes trial: A post hoc subgroup analysis of EMPA-REG outcome
20236 citationsauthor #8
Baseline determinants of remission of type 2 diabetes in response to short‐term insulin‐based therapy: The pivotal role of beta‐cell function
20233 citationsauthor #5
The vascular function effects of adding exenatide or meal insulin to basal insulin therapy in early type 2 diabetes
20232 citationsauthor #6
Treatment of Gestational Diabetes Mellitus and Maternal Risk of Diabetes After Pregnancy.
202315 citationsauthor #6
Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial.
202323 citationsauthor #17
Concordance of A1C, Fasting Glucose, and Oral Glucose Tolerance Test Criteria for Defining Remission of Diabetes.
20232 citationsauthor #5
255-OR: Postpartum Weight Retention and the Early Evolution of Cardiovascular Risk over the First 5 Years after Delivery
20230 citationsauthor #5
Deteriorating beta cell function is the dominant determinant of progression from normal glucose tolerance to prediabetes/diabetes in young women following pregnancy
202315 citationsauthor #7
Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering
20234 citationsauthor #13
180-OR: Baseline Predictors of Remission of Type 2 Diabetes in Response to Short-Term Insulin-Based Therapy—The Pivotal Role of Beta-Cell Function
20230 citationsauthor #5
Response to Comment on Lachin et al. Association of Estimated Time-in-Range Capillary Glucose Levels Versus HbA1c With Progression of Microvascular Complications in the Diabetes Control and Complications Trial. Diabetes Care 2022;45:2445-2448.
20222 citationsauthor #5
Risk of Foot Ulcer and Lower-Extremity Amputation Among Participants in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study.
202267 citationsauthor #8
The metabolic effects of adding exenatide to basal insulin therapy when targeting remission in early type 2 diabetes in a randomized clinical trial
202212 citationsauthor #5
Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes
202225 citationsauthor #3
Association of Estimated Time-in-Range Capillary Glucose Levels Versus HbA1c With Progression of Microvascular Complications in the Diabetes Control and Complications Trial.
202212 citationsauthor #5
Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition?
202240 citationsauthor #6
Treating Gestational Diabetes Reduces Birth Weight but Does Not Affect Infant Adiposity Across the 1st Year of Life.
20228 citationsauthor #6
Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial
20229 citationsauthor #17
721-P: Insulin-Sparing Effects of Oral Semaglutide: An Analysis of PIONEER 8
20222 citationsauthor #6
Treatment with glucagon‐like peptide‐1 receptor agonists and incidence of dementia: Data from pooled double‐blind randomized controlled trials and nationwide disease and prescription registers
2022173 citationsauthor #9
Early Trajectory of Estimated Glomerular Filtration Rate and Long-term Advanced Kidney and Cardiovascular Complications in Type 1 Diabetes.
20225 citationsauthor #8
Determinants of Small for Gestational Age in Women With Type 2 Diabetes in Pregnancy: Who Should Receive Metformin?
202223 citationsauthor #2
249-OR: Growth Trajectories of MiTy Kids' Offspring According to Intrauterine Growth Status
20221 citationsauthor #6
RF16 | PSUN155 Empagliflozin and the risk of nephrolithiasis
20220 citationsauthor #6
Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials
2022162 citationsauthor #19
Optimal Frequency of Urinary Albumin Screening in Type 1 Diabetes.
20224 citationsauthor #5
248-OR: MiTy Kids: Follow-Up of Offspring Exposed to Metformin In-Utero in Mothers with Type 2 Diabetes in the MiTy Trial
20223 citationsauthor #5
The impact of canagliflozin on the risk of neuropathy events: a post-hoc exploratory analysis of the CREDENCE trial.
202217 citationsauthor #18
Empagliflozin in patients with type 2 diabetes mellitus and chronic obstructive pulmonary disease.
20228 citationsauthor #4
Nephrotic-range proteinuria in type 2 diabetes: Effects of empagliflozin on kidney disease progression and clinical outcomes
202116 citationsauthor #4
Empagliflozin Reduces Myocardial Extracellular Volume in Patients With Type 2 Diabetes and Coronary Artery Disease.
202178 citationsauthor #13
The discovery of insulin in Toronto: beginning a 100 year journey of research and clinical achievement
202129 citationsauthor #2
Effects of linagliptin vs glimepiride on cognitive performance in type 2 diabetes: results of the randomised double-blind, active-controlled CAROLINA-COGNITION study
202139 citationsauthor #6
Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA‐REG OUTCOME trial
202118 citationsauthor #11
Patient Phenotypes and SGLT-2 Inhibition in Type 2 Diabetes: Insights From the EMPA-REG OUTCOME Trial.
202114 citationsauthor #4
Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial
202112 citationsauthor #15
Author response for "The Ongoing Evolution of Basal Insulin Therapy over 100 Years and its Promise for the Future"
20210 citationsauthor #2
Short‐term intensive insulin as induction and maintenance therapy for the preservation of beta‐cell function in early type 2 diabetes (RESET‐IT Main): A 2‐year randomized controlled trial
202113 citationsauthor #10
133-LB: Canagliflozin Improves Cardiovascular and Renal Outcomes across Broad Geographic Regions: Results from CREDENCE
20210 citationsauthor #10
Correction to: The discovery of insulin in Toronto: beginning a 100 year journey of research and clinical achievement
20210 citationsauthor #2
Empagliflozin facilitates sustained insulin dose reductions in patients with type 2 diabetes and cardiovascular disease: the EMPA-REG OUTCOME trial
20210 citationsauthor #10
Empagliflozin Reduces the Total Burden of All-cause Hospitalisations and All-cause Mortality in the EMPA-REG OUTCOME trial
20210 citationsauthor #2
The ongoing evolution of basal insulin therapy over 100 years and its promise for the future
202120 citationsauthor #2
Serum urate and cardiovascular events in the DCCT/EDIC study
20215 citationsauthor #14
319-OR: Effects of Empagliflozin on Markers of Liver Steatosis and Fibrosis and Their Relation to Cardiorenal Outcomes in the EMPA-REG OUTCOME Trial
20210 citationsauthor #3
Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA‐REG OUTCOME trial
202116 citationsauthor #3
Empagliflozin Reduced the Total Burden of Events Leading to or Prolonging Hospitalisation in EMPA-REG OUTCOME
20210 citationsauthor #5
Effect of empagliflozin on cardiorenal outcomes and mortality according to body mass index: A subgroup analysis of the EMPA‐REG OUTCOME trial with a focus on Asia
202120 citationsauthor #5
Impact of polyvascular disease with and without co‐existent kidney dysfunction on cardiovascular outcomes in diabetes: A post hoc analysis of EMPA‐REG OUTCOME
202113 citationsauthor #10
Use of diuretics and outcomes in patients with type 2 diabetes: findings from the EMPA‐REG OUTCOME trial
202134 citationsauthor #6
Subtypes of gestational diabetes and future risk of pre-diabetes or diabetes
202131 citationsauthor #6
Insulin and insulin analogs as antidiabetic therapy: A perspective from clinical trials.
202148 citationsauthor #3
131-LB: The Impact of Canagliflozin on the Risk of Neuropathy Events: Results from the CREDENCE Trial
20210 citationsauthor #16
Cardiovascular and kidney implications of the initial response in estimated glomerular filtration rate to sodium glucose cotransporter-2 inhibition with empagliflozin: the ‘eGFR dip’ in EMPA-REG OUTCOME
20210 citationsauthor #10
Effect of Empagliflozin on Total Events of Myocardial Infarctions by Subtype in the EMPA-REG OUTCOME Trial
20211 citationsauthor #3
Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the EMPA‐REG OUTCOME trial
202155 citationsauthor #7
Adipose Tissue Insulin Resistance Is Longitudinally Associated With Adipose Tissue Dysfunction, Circulating Lipids, and Dysglycemia: The PROMISE Cohort
202129 citationsauthor #7
Cardio/Kidney Composite End Points: A Post Hoc Analysis of the EMPA‐REG OUTCOME Trial
202115 citationsauthor #5
Author response for "The Effects of Canagliflozin on Heart Failure and Cardiovascular Death by Baseline Participant Characteristics: Analysis of the CREDENCE Trial"
20210 citationsauthor #15
Erratum to: Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes (t2d): the carmelina randomised controlled trial
20211 citationsauthor #15
Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis.
202142 citationsauthor #21
Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER
2021176 citationsauthor #12
The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial
202114 citationsauthor #15
790-P: Empagliflozin Reduced the Total Burden of Events Leading to or Prolonging Hospitalization in EMPA-REG OUTCOME
20210 citationsauthor #4
Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose co-transporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial.
2020172 citationsauthor #10
956-P: Efficacy and Safety of Oral Semaglutide When Added to Basal, Premix, or Basal-Bolus Insulin
20202 citationsauthor #7
Heart failure and renal outcomes according to baseline and achieved blood pressure in patients with type 2 diabetes: results from EMPA-REG OUTCOME.
202020 citationsauthor #8
EFFECTS OF CANAGLIFLOZIN ON CARDIOVASCULAR, RENAL AND SAFETY OUTCOMES BY BASELINE LOOP DIURETIC USE: DATA FROM THE CREDENCE TRIAL
20204 citationsauthor #18
Consistent cardiovascular (CV) benefit of empagliflozin over the spectrum of CV risk factor control in EMPA-REG OUTCOME
20201 citationsauthor #8
926-P: Cardiovascular (CV) and Hypoglycemia Outcomes across Age Groups in People with Type 2 Diabetes (T2D) in the CAROLINA Trial
20200 citationsauthor #6
Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial.
2020130 citationsauthor #22
Short‐Term Changes in Albuminuria and Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EMPA‐REG OUTCOME Trial
202057 citationsauthor #4
1128-P: Empagliflozin and Obstructive Sleep Apnea (OSA): Exploratory Analysis from the EMPA-REG OUTCOME Trial
20200 citationsauthor #5
PATIENT PHENOTYPES AND SGLT-2 INHIBITION IN TYPE 2 DIABETES MELLITUS: INSIGHTS FROM THE EMPA-REG OUTCOME TRIAL
20202 citationsauthor #4
Empagliflozin for Patients With Presumed Resistant Hypertension: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial
202038 citationsauthor #7
THE ASSOCIATION BETWEEN POLYVASCULAR DISEASE AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES: A SUB-ANALYSIS OF EMPA-REG OUTCOME
20200 citationsauthor #10
Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial
202047 citationsauthor #10
Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2: Subgroup Analysis of the Randomized CREDENCE Trial.
2020112 citationsauthor #19
Cardiovascular outcomes and LDL-cholesterol levels in EMPA-REG OUTCOME®
202012 citationsauthor #2
1144-P: Patient Phenotypes and SGLT2 Inhibition in Type 2 Diabetes Mellitus: Insights from the EMPA-REG OUTCOME Trial
20200 citationsauthor #4
Can the cardiovascular risk reductions observed with empagliflozin in the EMPA‐REG OUTCOME trial be explained by concomitant changes seen in conventional cardiovascular risk factor levels?
202015 citationsauthor #7
Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA‐REG OUTCOME trial
202029 citationsauthor #3
26-OR: Acute Declines in EGFR during Treatment with Canagliflozin and Its Implications for Clinical Practice: Insights from CREDENCE
20200 citationsauthor #17
Sex Disparities in Cardiovascular Outcome Trials of Populations With Diabetes: A Systematic Review and Meta-analysis
202049 citationsauthor #4
162-OR: Interrelationship between Hypoglycemia (HYPO) and Cardiovascular (CV) and Mortality Outcomes in the CAROLINA Trial
20200 citationsauthor #4
Analysis of first plus recurrent cardiovascular (CV) and hospitalisation events in the CAROLINA trial
20200 citationsauthor #9
The impact of empagliflozin on kidney injury molecule-1: a subanalysis of the Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients with Type 2 Diabetes CardioLink-6 trial.
202027 citationsauthor #10
1-OR: Analyses of First Plus Recurrent Cardiovascular (CV) and Hospitalization Events in the CAROLINA Trial
20200 citationsauthor #9
Effects of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the LEADER and SUSTAIN 6 trials
202063 citationsauthor #11
Abstract 14962: Empagliflozin’s Cardiovascular Impact in High-Risk Patients With Type 2 Diabetes and Obstructive Pulmonary Disease: An Inquiry From EMPA-REG OUTCOME
20200 citationsauthor #3
Risk factors for kidney disorders in patients with type 2 diabetes at high cardiovascular risk: An exploratory analysis (DEVOTE 12)
202010 citationsauthor #7
SAT-156 RENAL, CARDIOVASCULAR, AND SAFETY OUTCOMES OF CANAGLIFLOZIN ACCORDING TO BASELINE ALBUMINURIA: A CREDENCE SECONDARY ANALYSIS
20203 citationsauthor #13
LB005KIDNEY IMPLICATIONS OF THE INITIAL EGFR RESPONSE TO SGLT2 INHIBITION WITH EMPAGLIFLOZIN: THE ‘EGFR DIP’ IN EMPA-REG OUTCOME
20201 citationsauthor #10
CANAGLIFLOZIN (CANA) REDUCES CARDIOVASCULAR (CV) AND RENAL EVENTS INDEPENDENT OF BASELINE HEART FAILURE (HF): A CREDENCE SECONDARY ANALYSIS
20207 citationsauthor #17
Neighborhood walkability and risk of gestational diabetes
202010 citationsauthor #6
P1019CANAGLIFLOZIN AND RISK OF SKIN AND SOFT TISSUE INFECTIONS IN PEOPLE WITH DIABETES MELLITUS AND KIDNEY DISEASE - A POST-HOC ANALYSIS OF THE CREDENCE TRIAL
20200 citationsauthor #17
952-P: Incident and Recurrent Hypoglycemia with Linagliptin and Glimepiride in the CAROLINA Trial
20200 citationsauthor #1

TIMELINE

1966 2 citations

1972 19 citations

1974 135 citations

1976 0 citations

1977 351 citations

1978 66 citations

1979 228 citations

1980 172 citations

1981 318 citations

1982 124 citations

1983 48 citations

1984 161 citations

1985 93 citations

1986 78 citations

1987 115 citations

1988 41 citations

1989 170 citations

1990 23 citations

1991 18 citations

1992 50 citations

1993 164 citations

1994 386 citations

1996 659 citations

1997 926 citations

1998 1,232 citations

1999 827 citations

2000 1,384 citations

2001 3,728 citations

2002 1,073 citations

2003 2,701 citations

2004 1,837 citations

2005 6,177 citations

2006 4,149 citations

2007 2,037 citations

2008 3,040 citations

2009 9,547 citations

2010 2,462 citations

2011 2,104 citations

2012 1,191 citations

2013 2,679 citations

2014 3,121 citations

2015 7,448 citations

2016 5,100 citations

2017 5,799 citations

2018 2,745 citations

2019 8,865 citations

2020 1,597 citations

2021 739 citations

2022 573 citations

2023 130 citations

Unknown 0 citations

B. Zinman

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT